Silexion Therapeutics to Showcase RNAi Cancer Therapies at Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotech company specializing in RNA interference (RNAi) therapies for KRAS-driven cancers, has announced its participation in the upcoming 2024 Maxim Healthcare Virtual Summit. The summit, scheduled from October 15 to 17, 2024, will feature a fireside chat with Silexion's leadership on October 17 at 9:30 am ET.

The presentation at this prestigious healthcare summit underscores the growing interest in Silexion's innovative approach to cancer treatment. KRAS mutations are the most common oncogenic drivers in human cancers, and Silexion's focus on developing RNAi therapies targeting these mutations positions the company at the forefront of a potentially transformative area of oncology research.

Silexion's CEO Ilan Hadar and Chief Scientific and Development Officer Dr. Mitchell Shirvan will participate in the fireside chat, providing insights into the company's pipeline and progress. This event offers a valuable opportunity for investors and industry observers to gain a deeper understanding of Silexion's therapeutic strategies and their potential impact on the treatment landscape for solid tumors.

The company's lead product, LODER™, has already shown promising results in a Phase 2 trial for non-resectable pancreatic cancer, a notoriously difficult-to-treat malignancy. Additionally, Silexion is advancing SIL-204, a next-generation siRNA candidate designed to target a broader range of KRAS mutations, which has demonstrated significant potential in preclinical studies.

Silexion's participation in the Maxim Healthcare Virtual Summit comes at a time when the biotechnology sector is increasingly focusing on precision medicine approaches to cancer treatment. The company's RNAi therapies represent a novel strategy in the fight against KRAS-driven cancers, potentially offering new hope for patients with limited treatment options.

As Silexion continues to progress its clinical programs and expand its pipeline, presentations at events like the Maxim Healthcare Virtual Summit provide crucial visibility to potential investors and partners. The company's innovative approach to targeting KRAS mutations could have far-reaching implications for the treatment of various solid tumors, making Silexion a company to watch in the oncology space.